Sylvant

Active Ingredient(s): Siltuximab
FDA Approved: * April 22, 2014
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6.[1][2] Siltuximab has been investigated for the treatment of neoplastic diseases:[3] metastatic renal cell cancer,[4] prostate cancer,[5] and Castleman's disease,[6][7] among ot... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Sylvant 100 mg Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 57894-420

Labeler:

Janssen Biotech, Inc.

Sylvant 400 mg Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 57894-421

Labeler:

Janssen Biotech, Inc.

Sylvant 100 mg Intravenous Injection, Powder, for Solution

NDC: 73090-420

Labeler:

Eusa Pharma (Uk) Ltd

Sylvant 400 mg Intravenous Injection, Powder, for Solution

NDC: 73090-421

Labeler:

Eusa Pharma (Uk) Ltd